Rhythm Biosciences (ASX:RHY) made a sale of its geneType cancer risk assessment test in Manila, Philippines, the first sale in Southeast Asia, according to a Thursday Australian bourse filing.
The firm partnered with Digistain in the region earlier in March. The Digistain team effectively completed the initial commercial pilot and will now scale sales across the Philippines before setting up pilots in other Southeast Asian markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.